Browse All

Current Filters

CLEAR FILTER x

TITLE

Phase 3, Open-Label, Safety Extension Study of Oral Edaravone (Radicava ORS®) Administered Over 96 Weeks in Patients with ALS (MT-1186-A03)

Author:Genge, Angela   Pattee, Gary   Sobue, Gen   Aoki, Masashi   Yoshino, Hiide   Couratier, Philippe   Lunetta, Christian   Petri, Susanne   Selness, Daniel   Todorovic, Vesna   Hirai, Manabu   Salah, Alejandro   Apple, Stephen   Wamil, Art   Kalin, Alexander   Jackson, Carlayne A.   

Session Name:S27: General Neurology 2  

Topic:General Neurology  

Program Number:S27.007  

Author Institution:Montreal Neurological Institute and Hospital, Montreal, QC, Canada  University of Nebraska Medical Center, Lincoln, NE  Nagoya University Graduate School of Medicine, Aichi Medical University, Nagoya, Aichi, Japan  Tohoku University School of Medicine, Sendai, Miyagi, Japan  Neurology Clinic, Chiba, Japan  CRMR SLA Service de Neurologie, CHU de Limoges, Limoges, France  Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milano , Milan, Italy  Hannover Medical School, Hannover, Germany  Mitsubishi Tanabe Pharma America, Inc., Jersey City, NJ  Mitsubishi Tanabe Pharma Europe Ltd., London, United Kingdom  Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan  University of Texas Health Science Center at San Antonio, San Antonio, TX